Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Jan 10;12(1):323.
doi: 10.1038/s41598-021-03734-6.

Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries

Marta Solans  1   2 , Arantza Sanvisens  3 , Alberto Ameijide  4 , Susana Merino  5 , Dolores Rojas  6 , Araceli Alemán  6 , Emilia Banqueri  7 , Matilde Chico  8 , Ana Isabel Marcos  9 , Visitación de Castro  10 , Leire Gil  10 , Arantza López de Munain  10 , Montse Puigdemont  11 , Maria-José Sánchez  12   13 , Josefina Perucha  14 , Patricia Ruiz-Armengol  15 , Mª Dolores Chirlaque  12   16 , Marcela Guevara  12   17 , Marià Carulla  4 , Rafael Marcos-Gragera  12   3   11
Affiliations
Multicenter Study

Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries

Marta Solans et al. Sci Rep. .

Abstract

Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002-2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASRE), incidence trends, and estimates for 2021 were calculated. ASRE per 100,000 inhabitants was 5.14 (95% CI: 5.00-5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59-4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79-4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78-0.88) for MDS/MPN, 0.35 (95% CI: 0.32-0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53-0.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Age-specific incidence rates of broad categories of myeloid neoplasms diagnosed in Spain during 2002–2013. AML acute myeloid leukemia, AL acute leukemia, MDS myelodysplastic syndromes, MPN myeloproliferative neoplasms, NOS not-otherwise specified. Rates are expressed per 100,000 person-years.
Figure 2
Figure 2
Age-standardized incidence rates (ASRE) of myeloid neoplasms diagnosed in Spain during 2002–2013 by region. AML acute myeloid leukemia, AL acute leukemia of ambiguous lineage, MDS myelodysplastic syndromes, MPN myeloproliferative neoplasms, NOS not-otherwise specified. Rates are expressed per 100,000 person-years.
See this image and copyright information in PMC

References

    1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2021;71:209–249. - PubMed
    1. Sant M, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–3734. - PubMed
    1. Jaffe ES, Harris NL, Stein H, Wardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; 2001.
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; 2008.
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; 2017.

Publication types